Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 6, 2005, Pages 609-616

  Nygren, Peter ^a   Hande, Kenneth ^b   Petty, Kevin J ^c   Fedgchin, Margaret ^c   Van Dyck, Kristien ^c   Majumdar, Anup ^c   Panebianco, Debbie ^c   De Smet, Marina ^c   Ahmed, Tuli ^c   Murphy, M Gail ^c   Gottesdiener, Keith M ^c   Cocquyt, Veronique ^d   Van Belle, Simon ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Aprepitant; Cancer; CYP3A4; Docetaxel; Drug interaction; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; APREPITANT; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 3A4; DOCETAXEL; UREA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD CELL COUNT; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; INFUSION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; NAUSEA; NEUTROPHIL; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; UREA BLOOD LEVEL;

ADMINISTRATION, ORAL; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; TAXOIDS;

EID: 21044452727     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0946-3     Document Type: Article

References (20)

1. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Guoguang JM, Eldridge K, Hippie A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
2. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119
3. de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Morgan KJ (2004) The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 40:403-410
4. Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SHL, Evans DC, Huskey SEW (2004) Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 32:1287-1292
5. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, Goldberg MR, Murphy G, Gottesdiener KM, Lines CR, Petty KJ, Blum RA (2003) Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 74:150-156
6. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832
7. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302
8. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH (2000) The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6:1255-1258
9. Goh BC (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683-3690
10. Yamamoto N (2004) Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 18:2301-2308
11. Engels FK, ten Tije AJ, Baker SD, Lee CKK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3 A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharm Ther 75:448-454
12. Aventis (2003) Taxotere (docetaxel) injection concentrate (package insert). Available at PDR Electronic Library: http:// www.thomsonhc.com/pdrel/ librarian. Accessed 5 April 2004
13. PPD Development (2003) Quantitation of docetaxel in human plasma via HPLC with MS/MS detection. Internal report.
14. Constanzer ML, Chavez-Eng CM, Dru J, Kline WF, Matuszewski BK (2004) Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors. J Chromatogr B 807:243-250
15. Hollander M, Wolfe DA (1973) Nonparametric statistical methods. John Wiley & Sons, New York
16. Jones B, Kenward MG (1989) The 2x2 cross-over trial with continuous data. In: Design and analysis of crossover trials. Chapman Hall, New York, pp 16-88
17. Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tate NS, Tkaczuk KH (2000) Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol 18:3288-3294
18. Shadle CR, Lee Y, Majumdar AK, Petty KJ, Gargano C, Bradstreet TE, Evans JK, Blum RA (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215-223
19. Slaviero KA (2004) Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57:44-53
20. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99-114